| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED FEBRUARY 2015. Refer to TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | infliximab (Remicade®) | |
| Formulation | 100 mg powder for concentrate for solution for infusion | |
| Reference number | 931 | |
| Indication | Treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Gastro-intestinal system | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 23/07/2012 | |
| Date of issue | 27/07/2012 | |
| NICE guidance | ||